Puma Biotechnology, Inc. (PBYI): Cash & Equivalents
$29.64M
As of 2025-12-31
$36.54M
As of 2026-06-30
-27.0%
3-year compound annual growth
-19.1%
5-year compound annual growth
-0.6%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $29.64M | -57.2% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $69.22M | -18.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $84.58M | +11.0% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $76.20M | +20.7% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $63.13M | -26.0% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $85.29M | +42.1% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $60.04M | -44.6% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $108.42M | +32.7% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $81.70M | -58.0% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $194.49M | +516.1% | 2018-03-09, Balance as of period end |
| 2015-12-31 | $31.57M | -18.1% | 2018-03-09, Balance as of period end |
| 2014-12-31 | $38.54M | -10.5% | 2017-03-01, Balance as of period end |
| 2013-12-31 | $43.04M | -68.7% | 2016-02-29, Balance as of period end |
| 2012-12-31 | $137.41M | +157.4% | 2015-03-02, Balance as of period end |
| 2011-12-31 | $53.38M | n/a | 2014-03-03, Balance as of period end |
| 2010-12-31 | $0 | n/a | 2013-04-01, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $29.64M | -57.2% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $238.20M | +93.5% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $184.84M | +256.4% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $112.83M | +33.7% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $84.85M | -17.1% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $287.42M | -48.7% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $134.66M | +11.3% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $222.00M | +48.0% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $230.52M | +56.5% |
Compare PBYI, ANAB, AKBA, IDYA side by side · Screen every company in Pharmaceutical Preparations ↗